What's the Place of Psychedelics in Mental Health? [STAT Summit 2026 Review #16]
Report 16. What's the Place of Psychedelics in Mental Health?
Part I. English Version
1. Event / Date & Time
Event: What's the Place of Psychedelics in Mental Health?
Conference: STAT Summit 2026
Date & Time: October 14, 2026 | 4:20 PM EDT
2. Participants
Speakers
- Steven E. Hyman, M.D. — Harvard University Distinguished Service Professor; Director, Program in Brain Health, Broad Institute of MIT and Harvard
- Kabir Nath — Chief Executive Officer, Compass Pathways
Moderator
- Elaine Chen — National Biotech Reporter, STAT
3. Summary
Psilocybin Development: Compass described Phase 3 studies of COMP360 for treatment-resistant depression and the possibility of limited-dose, durable benefit.
Evidence and Safety: The panel considered functional unblinding, placebo controls, response heterogeneity and safety monitoring in psychedelic trials.
Delivery and Access: Structured clinical monitoring, provider training, reimbursement and post-treatment support are central to any potential clinical rollout.
4. Main Discussion
Potential Benefits for Treatment-Resistant Depression
Compass Pathways CEO Kabir Nath described COMP360, a psilocybin-based investigational treatment for treatment-resistant depression. He said the company was preparing a rolling regulatory submission and anticipated a possible commercial launch the following year, contingent on review. Steven Hyman agreed that new options are needed because established antidepressants can act slowly, do not work for everyone and may lose effectiveness.
Nath reported that a single supervised administration in an approximately six-hour clinical session produced a clinically meaningful response in about one-quarter of treated patients, increasing to around 40% when a second dose was provided three weeks later. He said the company had blinded six-month observations from two Phase 3 studies and longer follow-up from one study, with some responders experiencing effects potentially lasting up to a year after two or three administrations.
These figures were presented by the company representative and need to be interpreted in the context of study definitions and populations. The session was not a full appraisal of comparative efficacy against existing therapies. The clinical proposition was rapid relief and potentially durable responses from a limited number of sessions rather than ongoing frequent dosing.
Trial Design, Blinding and Response Biomarkers
A central methodological concern was whether psychoactive effects allow patients or assessors to infer which study treatment was administered, compromising conventional blinding. Nath said Compass used three dose levels—including a low-dose control and intermediate dose—to investigate dose response and help evaluate the extent of unblinding. He reported that prior psychedelic use was self-reported by only about 6–7% of participants, making the study population largely inexperienced with these substances.
Hyman emphasized the heterogeneity of depression. Patients with similar diagnostic labels may have different underlying biological mechanisms and disease courses. Without biomarkers that identify likely responders, trials can average together individuals with very different treatment sensitivities. He suggested that biological predictors could eventually strengthen clinical evidence and more precisely guide treatment selection.
The speakers did not resolve whether the subjective psychedelic experience is itself necessary for therapeutic benefit or whether direct pharmacologic effects account for most improvement. This uncertainty has consequences for study design, the choice of controls and expectations about psychotherapy during or after administration.
Safety, Supervision and Post-Dose Care
Nath described fatigue, nausea and headache as transient treatment-associated adverse events and said more than 80% of such effects had resolved by the following day. He did not report a treatment-arm imbalance in suicidality in the studies discussed, while acknowledging that acute suicidal risk was an exclusion criterion and that the enrolled population therefore did not represent all severely ill patients.
The clinical administration model was presented as a controlled, monitored setting rather than unsupervised self-treatment. Nath anticipated a risk evaluation and mitigation strategy (REMS) and provider training to address acute psychological experiences and decisions patients might make immediately afterward. Follow-up soon after dosing was described as important even when formal psychotherapy was not mandated as part of the pharmaceutical trial.
Hyman raised the distinction between psychological integration—the process of making sense of an intense experience—and direct medication effects. Nath said the company did not intend to prescribe one psychological therapy model for all patients, leaving treatment decisions to qualified clinicians. Both positions reinforced that safety management and treatment delivery cannot be considered separately from the drug itself.
Regulation, Patient Experience and Access
Nath said Compass had studied more than 1,000 patients across its development work, including two large controlled Phase 3 trials. He referred to earlier FDA breakthrough therapy designation and ongoing agency engagement, while cautioning that regulatory review remained necessary. The panel also discussed concerns that political enthusiasm for psychedelics could affect perceptions of scientific rigor; Hyman argued that credible evidence and careful monitoring must remain central.
A company-reported patient experience questionnaire had responses from about 80% of participants. Nath said that among respondents who received active treatment, more than 80% would be willing to repeat the experience if their physician recommended it. Such preference data illuminate acceptability but do not replace controlled measures of efficacy, safety or long-term functioning.
The moderator raised a possible price comparison with annual esketamine spending of approximately $50,000–$65,000, but Nath explicitly rejected treating this as a confirmed COMP360 price benchmark. He emphasized efforts to work with insurers and CMS on coverage, reimbursement codes and patient assistance. The discussion concluded that regulatory authorization alone would not guarantee broad and equitable access.
5. Insights
Rigorous Psychiatry R&D: Novel psychiatric therapies need controlled dose-response evidence, biomarker research and structured safety follow-up alongside promising patient response signals.
Implications for South Korea: Korea could consider evidence and safety requirements for emerging neuropsychiatric treatments while preparing appropriate clinical training and oversight structures.
Safe and Equitable Implementation: Collaboration among investigators, regulators, clinicians and payers will influence whether innovative mental-health therapies are delivered responsibly and accessibly.
![중국, GLP-1과 바이오산업의 미래 [STAT Summit 2026 Review #37]](https://static.wixstatic.com/media/a5656b_4948676866bd4394ae36f23a7a617ed1~mv2.jpg/v1/fill/w_980,h_314,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/a5656b_4948676866bd4394ae36f23a7a617ed1~mv2.jpg)
Comments